On Oct 17, major Wall Street analysts update their ratings for $Abbott Laboratories (ABT.US)$, with price targets ranging from $125 to $146.
Goldman Sachs analyst David Roman maintains with a buy rating.
J.P. Morgan analyst Robbie Marcus maintains with a buy rating, and maintains the target price at $135.
BofA Securities analyst Travis Steed maintains with a buy rating, and maintains the target price at $133.
Citi analyst Joanne Wuensch maintains with a buy rating.
UBS analyst Danielle Antalffy maintains with a buy rating, and adjusts the target price from $143 to $146.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
Abbott's slight surpassing of sales and EPS estimates reinforces the belief in the company's capacity to maintain double-digit MedTech sales growth in the coming period, alongside high single-digit growth in total sales. Analysts consider the enduring growth trajectory of Abbott's MedTech business to be undervalued. Furthermore, Abbott is recognized for offering a high-quality opportunity for high single-digit to low double-digit sales growth.
Following the Q3 results, Abbott is considered to be well-positioned to handle any competition from pulsed field ablation, and the potential for leadless pacing is expected to possibly spur growth in cardiac rhythm management to exceed 3%. While operational performance has been strong, it's assessed that current market expectations are already reflective of this, and the company's valuation is deemed reasonable when compared to its peers.
While acknowledging Abbott's positive trajectory post the third-quarter report, analysts continue to search for indications of enduring operating margin growth following the conclusion of the Testing phase.
Abbott's third-quarter sales exceeded consensus expectations, bolstered by a strong showing in the MedTech segment and revenue from COVID tests. The company also maintained its organic growth guidance for FY24 and raised the mid-point of its EPS forecast. Despite these positive developments, a cautious stance is maintained due to valuation and pending litigation concerns, though the company's performance is seen in a favorable light.
Abbott management indicated optimism about the company's potential for sustained high-single-digit revenue growth and double-digit earnings growth. Specifically, the CEO's comments suggested that high-single digit revenue and 10% earnings per share growth are seen as a feasible baseline. With numerous new offerings in the rapidly expanding Diabetes Care and Structural Heart markets, Abbott's comprehensive medical device portfolio appears poised for superior growth within the medical technology sector.
Here are the latest investment ratings and price targets for $Abbott Laboratories (ABT.US)$ from 14 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月17日，多家華爾街大行更新了$雅培 (ABT.US)$的評級，目標價介於125美元至146美元。
高盛集團分析師David Roman維持買入評級。
摩根大通分析師Robbie Marcus維持買入評級，維持目標價135美元。
美銀證券分析師Travis Steed維持買入評級，維持目標價133美元。
花旗分析師Joanne Wuensch維持買入評級。
瑞士銀行分析師Danielle Antalffy維持買入評級，並將目標價從143美元上調至146美元。
此外，綜合報道，$雅培 (ABT.US)$近期主要分析師觀點如下：
艾伯特輕微超出銷售和每股收益預期，增強了對公司在未來時期能夠保持雙位數醫療科技銷售增長以及總銷售高位數增長的信心，分析師認爲艾伯特醫療科技業務持續增長軌跡被低估。此外，艾伯特以提供高質量機會實現高單位數至低雙位數銷售增長而聞名。
在第三季度業績公佈後，艾伯特被認爲處於可以應對脈衝場消融競爭的有利位置，無心室起搏搭配的潛在可能性預計會刺激心臟節律管理增長超過3%。儘管運營績效良好，但有人認爲目前市場預期已經充分反映了這一點，與同行相比，公司的估值被認爲是合理的。
在第三季度報告後承認艾伯特積極軌跡的同時，分析師繼續尋找測試階段結束後持續營業利潤率增長跡象。
艾伯特第三季度銷售超出共識預期，強勁表現來自醫療科技領域和COVID測試收入。公司還維持了FY24年度有機增長指導，並提高了每股收益預測的中位數。儘管有這些積極發展，由於估值和未決訴訟的關注，保持謹慎立場，不過公司的表現被視爲積極的。
艾伯特管理層表示樂觀，認爲公司有潛力實現持續高位數銷售增長和雙位數盈利增長。具體來說，CEO的評論表明高單位數收入和10%每股收益增長被視爲可行基準。隨着在快速擴張的糖尿病護理和結構心臟市場推出衆多新產品，艾伯特全面的醫療器械組合似乎處於醫療技術行業內優越增長的有利位置。
以下爲今日14位分析師對$雅培 (ABT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
